AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 191 min read$ZNTL

HC Wainwright & Co. reiterates Buy rating on Zentalis Pharmaceuticals, $10 price target

HC Wainwright & Co. reiterated a Buy rating on Zentalis Pharmaceuticals with a $10 price target, implying a 369.5% upside from the Oct 16 close of $2.13. The company reported encouraging survival data for azenosertib, showing a median OS of 15.8 months in Cyclin E1-positive patients, and improved treatment management in ongoing trials.

Original reporting
tradingview.com
Published Oct 19, 2026, 10:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 10:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Zentalis Pharmaceuticals, $10 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$ZNTLBullishMed
01

Why it matters

Analyst upgrade may trigger short‑term buying interest and set a new price ceiling.

02

Market read

New clinical data and analyst upgrade provide fresh upside potential for Zentalis.

03

What to watch

Potential competition from other Cyclin E1‑targeted agents and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: today

Background

Analyst note from HC Wainwright highlighting new trial results and raising the price target.

Company-level read

Ticker impact

$ZNTLBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on Zentalis and set a $10 price target after reporting new interim overall survival data from the DENALI trial.

Expected impact

likely upward pressure as the market prices in the improved outlook and $10 target.

Evidence & confidence

The new survival data and reduced discontinuation rates suggest clinical progress, prompting the analyst to raise expectations.

Market effects

Sector

Positive data may lift sentiment for the broader oncology biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Modest, primarily affecting investors tracking early‑stage cancer therapeutics.

Counterpoint

What could challenge this read

The trial data are interim; outcomes could change in later phases, making the $10 target optimistic.

Key entities

  • company
    Zentalis Pharmaceuticals

    Biotech firm developing azenosertib for Cyclin E1‑positive cancers.

  • analyst
    HC Wainwright & Co.

    Equity research firm that issued the Buy rating and $10 target.

Read at source← All news

StoryZentalis reports biomarker-linked survival data for ovarian cancer drug

Also covered by

2 outlets

Related articles

OCT 19
$ZNTLHighAI 8/10

H.C. Wainwright reiterates Zentalis stock rating on survival data

H.C. Wainwright reiterated a Buy rating and $10.00 price target for Zentalis Pharmaceuticals (ZNTL) after positive survival data from its DENALI Part 1b trial. The stock has fallen 15% in a week, trading at $2.13. The trial showed cyclin E1-positive patients had a median overall survival of 15.8 months. The company has strong cash reserves and a high current ratio, supporting ongoing trials. Other analysts also initiated coverage with positive ratings and price targets.

investing.com2 min
OCT 19
$ZNTLHighAI 8/10

Zentalis reports survival data from azenosertib ovarian cancer study

Zentalis Pharmaceuticals reported interim overall survival results from the DENALI Part 1b study of azenosertib in platinum-resistant ovarian cancer. Cyclin E1-positive patients had a median survival of 15.8 months, while negative patients had 7.5 months. The study identified Cyclin E1 as a predictive biomarker. The company is continuing the DENALI program and conducting the Aspenova Phase III trial.

finance.yahoo.com2 min
OCT 19
$ZNTLMedAI 8/10

Zentalis Pharmaceuticals reports 15.8-month survival

Zentalis Pharmaceuticals (ZNTL) reported Phase 2 data showing 15.8-month median survival in Cyclin E1-positive ovarian cancer patients treated with azenosertib. The study lacked a chemotherapy control group. Shares fell 4.91% to $2.13 before the announcement. Zentalis expects topline DENALI Part 2 results in 1H 2027 and has sufficient cash to fund operations into late 2027.

mugglehead.com2 min
OCT 18
$ZNTLMedAI 8/10

In a study of an experimental ovarian cancer drug, median survival varied by tumor marker: 15.8 months versus 7.5.

Zentalis Pharmaceuticals (ZNTL) reported interim data for its ovarian cancer drug azenosertib, showing median overall survival of 15.8 months in Cyclin E1-positive patients vs. 7.5 months in negative patients. The data will be presented at ESMO Congress 2026. The company is advancing Phase 3 trials for azenosertib in this biomarker-selected population.

stocktitan.net2 min